Headache News

Biotech company Impel Neuropharma announced that its precision olfactory delivery device, or POD, safely delivered the company’s nasal dihydroergotamine-based INP104 treatment to patients with migraine.

A study presented at this year’s virtual PAINWeek meeting further demonstrated the safety and efficacy of remote electrical neuromodulation in reliving chronic migraine pain.

Galcanezumab was more effective than placebo in preventing migraine among patients with treatment-resistant migraine who also had other pain disorders, according to research presented at this year’s virtual PAINWeek.

Advanced therapies for the treatment of migraine events could provide more benefits with fewer side effects, according to findings published in the Journal of Neuro-Ophthalmology.

Calcitonin gene-related peptide, or CGRP, monoclonal antibodies reduced headache frequency among a small cohort of older adults with migraine, data show.

The FDA recently announced its approval of the cannabis-based Epidiolex, an oral solution to treat seizures in patients aged older than 1 year with tuberous sclerosis complex, a rare genetic disease that causes noncancerous tumors to grow in the brain and other parts of the body.

Various doses of the investigational agent atogepant, an orally administered calcitonin gene-related peptide receptor antagonist, significantly reduced mean monthly migraine days compared with placebo during a 12-week treatment period, according to phase 3 data from the ADVANCE trial released by the manufacturer.

Prazosin, approved in the 1970s to control hypertension and used off-label to eliminate PTSD-related nightmares, was recently shown to prevent post-traumatic headaches in veterans in a small randomized controlled trial.

Most patients in a small cohort used medical marijuana in lieu of other abortive medications to alleviate migraine pain, according to recent findings.

The first 10 websites found during a search of the words “headache” and “migraine” in the international version of Google featured content that required a reading level above what the NIH recommends, according to findings published in Headache.